Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Lilly’s Zepbound to enter the weight management market with competitive pricing

By Brian Buntz | November 8, 2023

Eli Lilly in the Drug Discovery & Development Pharma 50Lilly’s tirzepatide notched an FDA approval for chronic weight management, potentially clearly the way for billions in additional sales. Analysts have projected that the drug could fetch $26 billion in annual sales by 2030, with roughly two-thirds of that sum related to obesity​ treatment​. Bank of America analyst Geoff Meacham is even more optimistic, predicting that sales could hit $48 billion annually​.

The company is calling the obesity-branded version of the drug Zepbound, in contrast to Mounjaro, which won FDA approval for type 2 diabetes on May 13, 2022.  

Lily’s stock was up 3.20% to $619.13. Year-to-date, its share price is up almost 70%, in part as a result of strong sales prospects for tirzepatide. 

The table below outlines the starting cash prices for a range of GLP-1 receptor agonists. Lilly’s Zepbound, the obesity-branded version of tirzepatide, has a competitive starting price in the segment. With insurance, Zepbound could cost as low as $25 for eligible patients under a special savings program, while Wegovy could cost as little as $25 with insurance coverage and potentially more depending on individual insurance plan details.

Tirzepatide weight management FDA approval could drive further sales growth

Medication Cash price starting at (USD)
Wegovy $1,302
Zepbound $1,059.87
Ozempic $906
Trulicity $901
Rybelsus $906
Saxenda $1,302
Victoza $1,079
Bydureon Bcise $778

In recent quarters, tirzepatide as Mounjaro (for managing type 2 diabetes) have achieved quarter-over-quarter sales growth ranging from about 44% to 72%. The product won FDA approval for type 2 diabetes in May 2022.

Similarly, semaglutide sales growth has been astronomical in recent quarters. Year-over-year increases have been as high as 225% in Q1, 536.6% in Q2, and 733.9% in Q3 of 2023.

While head-to-head data are scant, tirzepatide may offer superior weight-loss support to semaglutide. While semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, tirzaptide targets both GLP-1 and the glucose-dependent insulinotropic polypeptide (GIP) receptor.

Strong weight loss support in studies

In a clinical trial, adults receiving the highest dose of Zepbound lost on average 48 pounds at the highest dose.

Overall, tirzepatide appears to support a greater mean percentage reduction in body weight that is higher than that of semaglutide in clinical trials, although more data would be needed to verify that conclusion. In indirect comparisons using data from the SURMOUNT-1 and STEP 1 trials, tirzepatide achieved a mean difference in weight loss of up to –5.92% compared to semaglutide, with high statistical significance (P < .001). In addition, the odds ratios for achieving a weight reduction of 5% or greater were superior with tirzepatide, at 2.61 for the 10 mg dose and 2.75 for the 15 mg dose. 

FDA approved the drug based on data from the phase 3 SURMOUNT-1 and SURMOUNT-2 trials. 

According to the FDA, roughly 70% of American adults have either obesity or overweight. The FDA had granted the therapy Priority Review and Fast Track designations given the urgent medical need for novel weight management therapies. 

To date, Lilly has struggled to manufacture sufficient quantities to meet demand.

Headwinds for growth of GLP-1 drugs include conservative insurers and the relatively high cost of the therapies.

Lilly will launch a savings card program for those with commercial insurance.


Filed Under: Metabolic disease/endicrinology
Tagged With: FDA approval, GLP-1 receptor agonists, market analysis, obesity treatment, Pharmaceutical Sales, Tirzepatide, weight management
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Eli Lilly in the Drug Discovery & Development Pharma 50
Lilly’s oral GLP-1 achieves up to 1.6% A1C reduction and 16 lb weight loss in late-stage diabetes trial
Mounjaro
GLP-1 use tripled among non-diabetics, hitting $5.8B in 2022
University of Ottawa students harness tobacco relative to grow Ozempic-like drugs
tirzepatide
JAMA: Potential rare vision complications linked to blockbuster GLP-1s
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE